Daniel O’Brien

Appearances

RISANKIZUMAB VERSUS USTEKINUMAB FOR THE ACHIEVEMENT OF CLINICAL REMISSION AND REDUCTION IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE TRIAL
Date
May 20, 2024
Improved clinical outcomes and normalization of objective markers of inflammation are important treatment targets per STRIDE-II consensus for patients (pts) with Crohn’s disease (CD)…
Presenter
Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Speakers
Marc Ferrante
Raja Atreya
Bincy Abraham
Houston Methodist
Alessandro Armuzzi
Laurent Peyrin-Biroulet
Peter Bossuyt
Miguel Regueiro
Cleveland Clinic
Stefan Schreiber
Remo Panaccione
Krisztina Gecse
Qian Cao
Ezequiel Neimark
Toni Anschutz
Stijn van Haaren
Daniel O’Brien
Geert D’Haens